Senayda Norabuena’s failure-to-warn claims under Illinois common law against Medtronic Inc. and Medtronic Sofamor Danek USA for injuries she allegedly suffered because of off-label use of an “Infuse Bone Graft/LT–Cage Lumbar Tapered Fusion Device” presented tricky questions about pre-emption under Sections 360k(a) and 337(a) of the Federal Food, Drug and Cosmetic Act.The Infuse was a Class III medical device, and the premarket approval Medtronic received from the FDA required use of a specific …